Therapeutic Drug Monitoring

Breakthrough technology for monitoring biotherapies

PROMISE technology for improved and personalized treatment

Monoclonal antibodies  offer unprecedent opportunity to drug development with remarkable efficacy and safety  and have significantly improved the prognosis of more than 14 millions patients with newdeclared cancers  and patients currently living with chronic inflammatory disease.

 

These novel drugs can be used either as a monotherapy or in combination, reinforcing the therapeutic Armamentarium of the clinicians. In these contexts, therapeutic monitoring of biotherapy has become a new preoccupation for clinicians.

 

It consists in monitoring the clearance of a monoclonal antibody, injected alone or in combination, in the serum of a patient. Thus, monitoring of biotherapies allows:

  • to determine precisely and objectively the patient response to a treatment.
  • to better control efficacy while anticipating therapeutic escape and secondary effects.

 

PROMISE will help you in
the implementation of TDM in your lab

and already offers patented solutions
and product line dedicated to this application